DDInter1837 DDInter119
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Toremifene {u} (Compound) resembles {v} (Compound) Doxylamine
Toremifene {u} (Compound) treats {v} (Disease) breast cancer
Toremifene {u} (Compound) binds {v} (Gene) ABCB1
Toremifene {u} (Compound) upregulates {v} (Gene) SQSTM1
Toremifene {u} (Compound) downregulates {v} (Gene) PMM2
Toremifene {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Toremifene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metolazone
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Toremifene (Compound) resembles Doxylamine (Compound)
Toremifene (Compound) treats breast cancer (Disease)
Toremifene (Compound) binds ABCB1 (Gene)
Toremifene (Compound) upregulates SQSTM1 (Gene)
Toremifene (Compound) downregulates PMM2 (Gene)
Toremifene (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Toremifene may lead to a major life threatening interaction when taken with Pazopanib